Contact Us

PW Case Review Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


FDA rejects Merck's Vioxx successor

Apr 27, 2007 | AP

The Food and Drug Administration rejected Merck & Co.'s request to market a successor to its withdrawn arthritis drug Vioxx in the United States, the drugmaker said.

The move was widely expected, after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug, Arcoxia.

Arcoxia is in the same class of drugs as Vioxx, which has become a poster child for drug safety problems.

Merck pulled Vioxx from the market in September 2004 after research showed it doubles risk of heart attacks and strokes. That triggered an avalanche of lawsuits more than 27,000 so far and a nosedive for Merck's stock price, which has since bounced back.

Despite the safety concerns in the United States, Arcoxia is on sale in 63 other countries, and Merck officials said as recently as Tuesday that they intend to keep working to get it on the U.S. market.

Arcoxia had been poised for approval until Vioxx was pulled from the market. Two months later, the FDA issued what's called an "approvable" letter, saying it could approve Arcoxia, but only if Merck provided further safety and efficacy information for the drug.

Merck has since produced results from further studies of Arcoxia, but doctors questioned those results because Merck compared Arcoxia in its tests to another painkiller that has elevated risk of heart attacks and strokes.

Peter S. Kim, president of Merck Research Laboratories, told company shareholders at their annual meeting Tuesday that "there is more long-term safety data on Arcoxia than" other drugs in the same class and traditional anti-inflammatory medicines.

"We are committed to working with the FDA to determine the best approach" to get it on the U.S. market, Kim said.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo